Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OTC Athlete’s Foot Drugs Scheduled For FDA Advisory Committee Review

This article was originally published in The Tan Sheet

Executive Summary

FDA's Nonprescription Drugs and Dermatologic & Ophthalmic Drugs advisory committees are scheduled to review OTCs used in treatment of interdigital tinea pedis at a May 6-7 meeting in Rockville, Md
Advertisement

Related Content

NDAC Will Evaluate Trial Design, Labeling For Athlete’s Foot OTCs
NDAC Will Evaluate Trial Design, Labeling For Athlete’s Foot OTCs
NDAC Will Evaluate Trial Design, Labeling For Athlete’s Foot OTCs
Antifungal drug products
Antifungal drug products

Topics

Advertisement
UsernamePublicRestriction

Register

PS096616

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel